COMPANY

Kolon TissueGene

HQ: Rockville, MD source · tissuegene.com ↗ · Mid-Atlantic

Keywords: cell therapy gene therapy musculoskeletal Degenerative Osteoarthritis Knee Osteoarthritis Degenerative Disc Disease TG-C TissueGene-C

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

2027-10 Trial start Phase 2: A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis source ↗
Jan 19, 2027 Trial start Phase 1: Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease source ↗
Dec 9, 2021 Trial start Phase 3: Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee source ↗
Oct 30, 2018 Trial start Phase 3: A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee source ↗
2011-05 Trial start Phase 2: Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee source ↗
2007-01 Trial start Phase 1: Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee source ↗

Jul 28, 2028 (ESTIMATED) · Phase 1 · Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease · NCT06144970
2028-10 (ESTIMATED) · Phase 2 · A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis · NCT05276011

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT03291470	Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee	Phase 3	Completed	Dec 9, 2021	Mar 6, 2024 (actual)
NCT05276011	A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis	Phase 2	Not yet recruiting	2027-10	2028-10 (estimated)
NCT06144970	Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease	Phase 1	Not yet recruiting	Jan 19, 2027	Jul 28, 2028 (estimated)
NCT03203330	A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee	Phase 3	Active, not recruiting	Oct 30, 2018	Jul 10, 2024 (actual)
NCT00599248	Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee	Phase 1	Completed	2007-01	2009-05 (actual)
NCT01221441	Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee	Phase 2	Completed	2011-05	2013-10 (actual)